Paired primary and metastatic tumor analysis of somatic mutations in synchronous and metachronous colorectal cancer

Cancer Research and Treatment

Volumn 49, Issue 1, 2017, Pages 161-167

  Kim, Kyu Pyo ^a   Kim, Jeong Eun ^a   Hong, Yong Sang ^a   Ahn, Sung Min ^a   Chun, Sung Min ^a   Hong, Seung Mo ^a   Jang, Se Jin ^a   Yu, Chang Sik ^a   Kim, Jin Cheon ^a   Kim, Tae Won ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Colorectal neoplasms; Genomics; Neoplasm metastasis

Indexed keywords

APC PROTEIN; B RAF KINASE; FORMALDEHYDE; PARAFFIN; PROTEIN P53; RAS PROTEIN; TUMOR MARKER;

ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; COLORECTAL CANCER; COMPARATIVE STUDY; DEMOGRAPHY; GENE; GENETIC ANALYZER; GENOTYPE; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; MEDICAL RECORD REVIEW; METACHRONOUS COLORECTAL CANCER; METASTASIS; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PIK3CA GENE; PRIMARY TUMOR; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SOFTWARE; SOMATIC MUTATION; SYNCHRONOUS COLORECTAL CANCER; CANCER GRADING; CANCER STAGING; COLORECTAL TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; GENOTYPING TECHNIQUE; HETEROZYGOSITY LOSS; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; SURVIVAL ANALYSIS;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE INSTABILITY; MUTATION; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 85010443049     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2015.490     Document Type: Article

References (18)

1. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-92.
2. Mahmoud N, Bullard Dunn K. Metastasectomy for stage IV colorectal cancer. Dis Colon Rectum. 2010;53:1080-92.
3. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Genet Med. 2013;15:517-27.
4. Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013;119:3776-83.
5. Kim YM, Lee SW, Chun SM, Kim DY, Kim JH, Kim KR, et al. Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples. PLoS One. 2014;9:e99451.
6. Mao C, Wu XY, Yang ZY, Threapleton DE, Yuan JQ, Yu YY, et al. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep. 2015;5:8065.
7. Knijn N, Mekenkamp LJ, Klomp M, Vink-Borger ME, Tol J, Teerenstra S, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011;104:1020-6.
8. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486: 532-6.
9. Kawamoto Y, Tsuchihara K, Yoshino T, Ogasawara N, Kojima M, Takahashi M, et al. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. Br J Cancer. 2012;107:340-4.
10. Lee SY, Haq F, Kim D, Jun C, Jo HJ, Ahn SM, et al. Comparative genomic analysis of primary and synchronous metastatic colorectal cancers. PLoS One. 2014;9:e90459.
11. Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol. 2014;15:454.
12. Ghiringhelli F, Hennequin A, Drouillard A, Lepage C, Faivre J, Bouvier AM. Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study. Dig Liver Dis. 2014;46:854-8.
13. Chu J, Goktepe O, Cheung WY. Natural history and outcomes of synchronous and metachronous colorectal cancers (CRC): a population-based analysis. J Clin Oncol. 2013;31(Suppl): Abstr 3593.
14. Slesser AA, Georgiou P, Brown G, Mudan S, Goldin R, Tekkis P. The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review. Clin Exp Metastasis. 2013;30:457-70.
15. Rose JS, Serna DS, Martin LK, Li X, Weatherby LM, Abdel-Misih S, et al. Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. Cancer. 2012;118:6243-52.
16. El Zouhairi M, Charabaty A, Pishvaian MJ. Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res. 2011;4:15-21.
17. Jiang JK, Chen YJ, Lin CH, Yu IT, Lin JK. Genetic changes and clonality relationship between primary colorectal cancers and their pulmonary metastases: an analysis by comparative genomic hybridization. Genes Chromosomes Cancer. 2005;43: 25-36.
18. Miranda E, Bianchi P, Destro A, Morenghi E, Malesci A, Santoro A, et al. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. Cancer. 2013;119:266-76.